Holen Sie sich die Stockscreener-App
40.85
0.15%
0.06
Handel nachbörslich:
40.85
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$40.79
Offen:
$40.94
24-Stunden-Volumen:
2.29M
Relative Volume:
1.21
Marktkapitalisierung:
$6.85B
Einnahmen:
$1.56B
Nettoeinkommen (Verlust:
$152.72M
KGV:
45.42
EPS:
0.8994
Netto-Cashflow:
$221.80M
1W Leistung:
-5.85%
1M Leistung:
-16.99%
6M Leistung:
+39.09%
1J Leistung:
+50.57%
1-Tages-Spanne:
$40.49
$41.12
1-Wochen-Bereich:
$40.49
$44.79
52-Wochen-Spanne:
$27.00
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, VTRS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
40.85 | 6.85B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-29 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Alkermes: Idiopathic Hypersomnia Could Expand LUMRYZ Into A Larger Growth, Margin Driver - Seeking Alpha
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works? - Insider Monkey
Alkermes Must Face Bulk Of Addiction Treatment Drug Suit - Law360
Alkermes Fails to Fend Off Addiction Treatment Antitrust Claim - Bloomberg Law News
Alkermes plc (AKD.DE) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
Alkermes PLC (ALKS) Shares Fall 3.2% -- GF Value Says Still Over - gurufocus.com
ALKS Reinstated by Goldman Sachs -- Rating Set to Neutral - gurufocus.com
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Goldman Sachs resumes Alkermes stock coverage with neutral rating - Investing.com
ALKS Looks 29.1% Overvalued on GF Value™ - gurufocus.com
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Yahoo
Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade) - Seeking Alpha
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290 - finance.yahoo.com
Annual Research Grant Program Expands Focus to Include Narcolepsy - sleepreviewmag.com
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
ALKS Reiterated by RBC Capital -- Price Target Maintained at $56 - gurufocus.com
ALKS Maintains by Baird -- Price Target Raised to $61.00 - gurufocus.com
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - finance.yahoo.com
Alkermes reports positive top-line Phase Ib trial data for ALKS 7290 - Clinical Trials Arena
TD Cowen reiterates Alkermes stock Buy rating on ADHD trial data - Investing.com Australia
Form 8K Alkermes plc. For: 21 September By Investing.com - Investing.com Nigeria
Alkermes Shares Jump 6.5% After ADHD Drug Shows Clinical Proof-of-Concept - finance.biggo.com
ALKS Looks 34.7% Overvalued on GF Value™ - gurufocus.com
Alkermes' ALKS7290 shows strong early results i... - Pluang
ALKS Reiterates by Needham -- Price Target Maintained at $62.00 - GuruFocus
Alkermes Announces Positive Phase 1 Topline Results for ALKS 7290 in ADHD Treatment - Kalkine Media
Stifel reiterates Alkermes stock rating on ADHD drug trial data By Investing.com - Investing.com Australia
Alkermes reports positive phase 1 data for ADHD drug candidate By Investing.com - Investing.com Australia
ALKS Looks 33.1% Overvalued on GF Value™ as ADHD Drug Shows Earl - gurufocus.com
Alkermes rises on phase 1 results for ADHD drug ALKS 7290 - Seeking Alpha
Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 - finance.yahoo.com
Why is Alkermes stock surging today? By Investing.com - Investing.com Canada
Alkermes stock jumps on positive ADHD drug trial results - Investing.com
Alkermes reports positive phase 1 data for ADHD drug candidate - Investing.com
Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHD - TradingView
Alkermes plc: Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - FinanzNachrichten.de
An ADHD drug in testing cut symptom scores by 19 points - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: A Look At Its 29.88% Potential Upside - DirectorsTalk Interviews
ALKS Looks 33.6% Overvalued on GF Value™ as Shares Drop to June Lows - GuruFocus
Alkermes PLC (ALKS) Shares Fall 7.1% -- What GF Score of 64 Tells Investors - gurufocus.com
Alkermes Falls as Investors Appear to Take Profits Despite No Obvious Negative Company Update - quiverquant.com
Anne Clem Whitaker is director at Alkermes (NASDAQ: ALKS) with no reported holdings - Stock Titan
Alkermes slides 7%, reaching multi-month low (ALKS:NASDAQ) - Seeking Alpha
Alkermes Strengthens Board with New Director Appointment - The Globe and Mail
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Form 8K Alkermes plc. For: 16 September By Investing.com - Investing.com Nigeria
Alkermes Expands Board with Anne C. Whitaker Appointment and Details Compensation Package - Kalkine Media
Alkermes Appoints Anne C. Whitaker to Board of Directors - citybiz
New Alkermes (NASDAQ: ALKS) director to get $600,000 in stock awards - Stock Titan
Alkermes Announces Appointment of Anne C. Whitaker to Board of D - GuruFocus
Alkermes appoints Anne Whitaker to board of directors By Investing.com - Investing.com Nigeria
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):